Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556–67.
2. Baldwin XL, Spanheimer PM, Downs-Canner S. A review of immune checkpoint blockade for the general surgeon. J Surg Res. 2023;281:289–98.
3. Myers SP, Sevilimedu V, Jones VM, et al. Impact of neoadjuvant chemoimmunotherapy on surgical outcomes and time to radiation in triple-negative breast cancer. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15359-w.
4. Kümmel SSP, Harbeck N, Takahashi M, Untch M, Boileau J, Cortes J, et al. Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab versus placebo for early TNBC: surgical outcomes from the phase 3 keynote-522 study. In: Presented at the 18th St Gallen international breast cancer conference 2023, 15–18 March 2023, Vienna, Austria.
5. Woodfin AYC, Teshome M, Kuerer H, Hunt KK, Meric-Bernstam F, Barcenas C, Sun S. Surgical outcomes in patients receiving pembrolizumab containing neoadjuvant systemic therapy regimens for triple-negative breast cancer. In: Presented at the American society of breast surgeons 24th annual meeting, 26–30 April 2023, Boston